Reduced Dose Post-Transplant Cyclophosphamide in Allogeneic Hematopoietic Cell Transplant

Key Points

• Reduced cyclophosphamide dosage improved patient outcomes post-transplant, enhancing recovery.
• Key metrics reveal a significant reduction in adverse effects by lowering dosage to optimal levels.
• Observational analysis employed data from multiple transplant centers, highlighting dosage effects on immune response.
• Results may enable tailored treatment strategies, promoting better recovery and reducing complications post-transplant.